User contributions
From 2009.igem.org
(Latest | Earliest) View (newer 20 | older 20) (20 | 50 | 100 | 250 | 500)
- 01:50, 22 October 2009 (diff | hist) Team:SupBiotech-Paris/Antitumor action (→Results [1,2])
- 01:38, 22 October 2009 (diff | hist) Team:SupBiotech-Paris/Treatement modeling (→First step : Tumour development according to time)
- 01:36, 22 October 2009 (diff | hist) Team:SupBiotech-Paris/Treatement modeling (→First step : Tumour development according to time)
- 01:32, 22 October 2009 (diff | hist) Team:SupBiotech-Paris/Tissue targeting (→Experimental method) (top)
- 01:31, 22 October 2009 (diff | hist) Team:SupBiotech-Paris/Tissue targeting (→Objective)
- 01:16, 22 October 2009 (diff | hist) Team:SupBiotech-Paris/Antitumor action (→Cancer cell line and reported gene)
- 01:15, 22 October 2009 (diff | hist) Team:SupBiotech-Paris/Antitumor action (→Cancer cell line and reported gene)
- 01:12, 22 October 2009 (diff | hist) Team:SupBiotech-Paris/Antitumor action (→Discussion)
- 01:02, 22 October 2009 (diff | hist) Team:SupBiotech-Paris/Ciblage Cellulaire (top)
- 00:57, 22 October 2009 (diff | hist) Team:SupBiotech-Paris/Antitumor action (→Experimental approach)
- 00:45, 22 October 2009 (diff | hist) Team:SupBiotech-Paris/Ethic (→The debate program)
- 00:39, 22 October 2009 (diff | hist) Team:SupBiotech-Paris/Ethic (→Summarization of reflections)
- 00:01, 22 October 2009 (diff | hist) Team:SupBiotech-Paris/Ethic (→Problematics related to the DVS project)
- 00:01, 22 October 2009 (diff | hist) Team:SupBiotech-Paris/Ethic (→Intellectual properties)
- 00:01, 22 October 2009 (diff | hist) Team:SupBiotech-Paris/Ethic (→The benefits/risks ratio)
- 23:58, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ethic (→Evolution control synthetic biology products)
- 23:55, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ethic
- 23:40, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Ethic
- 20:16, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Conclusion3
- 20:15, 21 October 2009 (diff | hist) Team:SupBiotech-Paris/Conclusion3
(Latest | Earliest) View (newer 20 | older 20) (20 | 50 | 100 | 250 | 500)